1 min read
Add as a preferred source on GoogleXilio Therapeutics Posts $9.98 Million in Q3 2026 Revenue
Collaboration and license revenue was $10.0 million, compared with $19.1 million a year earlier. Net loss per share was $0.30 on both basic and diluted bases.
Xilio Therapeutics generated $9.98 million in collaboration and license revenue in the third quarter of 2026, while recording a net loss of $0.30 per share on both basic and diluted bases.
The quarter ended Sept. 30. Revenue totaled $9.984 million, rounded to $10.0 million, compared with $19.1 million in the third quarter of 2025.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.